Skip to content

A Comparison of Two Target Mean Arterial Pressures in the Resuscitation of Hypotensive Trauma Patients

A Comparison of Two Target Mean Arterial Pressures in the Resuscitation of Hypotensive Trauma Patients Undergoing Laparotomy or Thoracotomy for Trauma: A Prospective Randomized Controlled Clinical Trial

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00459160
Enrollment
271
Registered
2007-04-11
Start date
2007-07-31
Completion date
2011-07-31
Last updated
2010-12-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hemorrhagic Shock, Multiple Trauma, Shock, Traumatic, Trauma, Wounds, Penetrating

Keywords

Hypotensive Resuscitation, Hypotensive Anesthesia, Hemorrhagic Shock, Penetrating Trauma

Brief summary

The goal of this study will be to determine if a lower than normal blood pressure during surgery for bleeding in the abdomen or chest will result in decreased bleeding and decreased chance of death.

Detailed description

For the proposed study, all trauma patients undergoing laparotomy or thoracotomy for trauma that had a systolic blood pressure \< 90 mmHg prior to going to the operating room will be randomized to one of two groups. The randomization will take place at the operating room door. The first group will have a target minimum mean arterial pressure of 50 mm Hg (LMAP) and the second group will have a target minimum mean arterial pressure of 65 mmHg (HMAP). Before the operating room and in all other aspects of their care the patients will be treated as per standard of care. Patients will then be followed to determine if there is a difference in 30 day survival between the two groups. Secondary outcome measures will be Sequential Organ Failure Assessment (SOFA) score, APACHE II, ARDS, ICU length of stay, myocardial ischemia, stroke, acidosis, coagulopathy by conventional labs and thromboelastogram, estimated blood loss, transfusion requirements, Glasgow Outcome Score, the presence of leukocyte apoptosis, the serum level of the pro-inflammatory cytokines, IL-6 and G-CSF, and the rate of infectious complications (VAP, UTI, Wound infections). Blood samples (20 ml each) will be taken at three time points: prior to randomization, immediately after the end of resuscitation protocol, and 24 hrs after randomization. Blood will be examined for the presence of leukocyte apoptosis and levels of IL-6 and G-CSF.

Interventions

PROCEDUREIntraoperative Hypotensive Resuscitation

Patients will have a target minimum MAP of 50 for the case

Sponsors

Baylor College of Medicine
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
12 Years to 45 Years
Healthy volunteers
No

Inclusion criteria

* All adult patients seen in the Ben Taub emergency center that have suffered a trauma, have a systolic blood pressure less than 90mm Hg, and are going to the operating room for a laparotomy or thoracotomy

Exclusion criteria

* Known or suspected head injury * Age \> 45 years old, \<= 12 years old * Incarcerated individuals * Pregnant women * Patients with an advanced directive that refuse resuscitation * Patients with opt-out bracelets that signify their refusal of participation in the project

Design outcomes

Primary

MeasureTime frame
30 day survival30 days

Secondary

MeasureTime frame
APACHE II30 days
ARDS30 days
ICU length of stay30 days
Ventilator-free days30 days
Myocardial ischemia30 days
Stroke30 days
Sequential Organ Failure Assessment (SOFA) score30 days
Coagulopathy by conventional labs and thromboelastogram30 days
Estimated blood loss30 days
Transfusion requirements30 days
Glasgow Outcome Score30 days
Quantification of leukocyte apoptosis2 days
Rate of infectious complications (VAP, UTI, wound infections).30 days
Acidosis (pH and BE)30 days

Countries

United States

Contacts

Primary ContactMatthew M Carrick, MD
mcarrick@bcm.edu713-873-4381

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026